Alpha 2.0
Login Register
» Authors » G Lledo

G Lledo

Explore the profile of G Lledo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 37
Citations 633
Followers 0
Related Specialties
Oncology
Pediatrics
Endocrinology
Top 10 Co-Authors
R Gracia
T Andre
C Louvet
J Martinez-Laso
P Artru
A de Gramont
R Barrio
J M Martin-Villa
A Arnaiz-Villena
M Nistal
Published In
An Esp Pediatr
Ann Oncol
Hum Genet
J Clin Oncol
Br J Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Capi-score: a quantitative algorithm for identifying disease patterns in nailfold videocapillaroscopy
Gracia Tello B, Gracia Tello B, Saez Comet L, Saez Comet L, Lledo G, Lledo G, et al.
Rheumatology (Oxford) . 2024 Mar; 63(12):3315-3321. PMID: 38530791
Objectives: EULAR supports the use of nailfold videocapillaroscopy (NVC) for identifying disease patterns (DPs) associated with SSc and RP. Recently, EULAR proposed an easy-to-manage procedure, a so-called Fast Track algorithm,...
2.
Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
Azria D, Doyen J, Jarlier M, Martel-Lafay I, Hennequin C, Etienne P, et al.
Ann Oncol . 2017 Sep; 28(10):2436-2442. PMID: 28961836
Background: Outcome of intermediate risk rectal cancer may be improved by the addition of oxaliplatin during 5-fluoruracil concomitant neoadjuvant chemoradiotherapy. The purpose of this study is to analyze the main...
3.
Cost-minimisation analysis in first-line treatment of metastatic colorectal cancer in France: XELOX versus FOLFOX-6
Perrocheau G, Bennouna J, Ducreux M, Hebbar M, Ychou M, Lledo G, et al.
Oncology . 2011 Mar; 79(3-4):174-80. PMID: 21358204
Objective: In a recent randomized study, we demonstrated that XELOX (oxaliplatin + oral capecitabine) was well tolerated and not inferior in terms of efficacy to the infusional FOLFOX-6 regimen in...
4.
Novel (60%) and recurrent (40%) androgen receptor gene mutations in a series of 59 patients with a 46,XY disorder of sex development
Audi L, Fernandez-Cancio M, Carrascosa A, Andaluz P, Toran N, Piro C, et al.
J Clin Endocrinol Metab . 2010 Feb; 95(4):1876-88. PMID: 20150575
Background: Androgen receptor (AR) gene mutations are the most frequent cause of 46,XY disorders of sex development (DSD) and are associated with a variety of phenotypes, ranging from phenotypic women...
5.
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer
Conroy T, Hebbar M, Bennouna J, Ducreux M, Ychou M, Lledo G, et al.
Br J Cancer . 2009 Nov; 102(1):59-67. PMID: 19920832
Background: A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic colorectal cancer. A...
6.
[Definitive treatment of anal canal carcinoma with radiotherapy: adverse impact of a pre-radiation resection. A retrospective study of 57 patients treated with curative intent]
Coquard R, Cenni J, Artru P, Chalabreysse P, Queneau P, Taieb S, et al.
Cancer Radiother . 2009 Oct; 13(8):715-20. PMID: 19854092
Purpose: To describe retrospectively the overall survival, the cancer specific survival and the tumor control in an homogeneous series of patients with epidermoid carcinoma of the anal canal treated with...
7.
FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: an exploratory cohort of the GERCOR OPTIMOX1 study
Chibaudel B, Tournigand C, Artru P, Andre T, Cervantes A, Figer A, et al.
Ann Oncol . 2009 May; 20(8):1383-6. PMID: 19465426
Background: Alkaline phosphatase (ALP) is a strong prognostic factor in patients with metastatic colorectal cancer (MCRC). Patients with ALP more than three times the upper limit of normal (ULN) were...
8.
First-line simplified GEMOX (S-GemOx) versus classical GEMOX in metastatic pancreatic cancer (MPA): results of a GERCOR randomized phase II study
Afchain P, Chibaudel B, Lledo G, Selle F, Bengrine-Lefevre L, Nguyen S, et al.
Bull Cancer . 2009 May; 96(5):E18-22. PMID: 19435690
Purpose: GemOx was defined as a D1-D2 schedule, based on preclinical data. In order to improve convenience for patients, we evaluated a simplified D1-D1 GemOx regimen (S-GemOx) in MPA. Patients...
9.
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study
Bidard F, Tournigand C, Andre T, Mabro M, Figer A, Cervantes A, et al.
Ann Oncol . 2009 Jan; 20(6):1042-7. PMID: 19153116
Background: Second-line irinotecan-based chemotherapy is commonly used in metastatic colorectal cancers after first-line oxaliplatin-based chemotherapy. No standard schedule of irinotecan has been established in this situation. Patients And Methods: Metastatic...
10.
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer
Bouchahda M, Macarulla T, Spano J, Bachet J, Lledo G, Andre T, et al.
Crit Rev Oncol Hematol . 2008 Apr; 67(3):255-62. PMID: 18400508
Background: Few data are available from clinical trials for elderly patients receiving cetuximab. Patients And Methods: The clinical data of consecutive patients aged > or =70 years given cetuximab for...